INTS - Intensity Therapeutics, Inc Stock Price, Fair Value and News
3.86USD-0.14Â (-3.50%)Delayed
Market Summary
USD3.86-0.14
Delayed-3.50%
INTS Stock Price
View Fullscreen
INTS RSI Chart
INTS Valuation
INTS Price/Earnings (Trailing)
INTS Profitability
INTS Fundamentals
INTS Earnings
Breaking Down INTS Revenue
Last 7 days
-1.5%
Last 30 days
-15.2%
Last 90 days
-18.6%
How does INTS drawdown profile look like?
INTS Financial Health
INTS Investor Care
Which funds bought or sold INTS recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| May 02, 2024 | Sigma Planning Corp | added | 38.98 | -46,258 | 248,919 | 0.01% |
| May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
| Apr 29, 2024 | COMMONWEALTH EQUITY SERVICES, LLC | new | - | 54,000 | 54,000 | -% |
| Apr 25, 2024 | Mesirow Financial Investment Management, Inc. | added | 29.26 | -63,177 | 229,720 | -% |
| Apr 24, 2024 | BROWN ADVISORY INC | new | - | 819,135 | 819,135 | -% |
| Apr 22, 2024 | SAPIENT CAPITAL LLC | added | 406 | 3,548,760 | 5,262,760 | 0.12% |
| Mar 11, 2024 | VANGUARD GROUP INC | new | - | 711,901 | 711,901 | -% |
| Feb 14, 2024 | Royal Bank of Canada | new | - | - | - | -% |
| Feb 14, 2024 | STATE STREET CORP | new | - | 124,265 | 124,265 | -% |
| Feb 14, 2024 | BANK OF AMERICA CORP /DE/ | new | - | 52.00 | 52.00 | -% |
Are Funds Buying or Selling INTS?
Calls
Puts
Net Call Options
No. of Funds
Unveiling Intensity Therapeutics, Inc's Major ShareHolders
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 13, 2024 | bender lewis h | 16.1% | 2,245,000 | SC 13G |
Recent SEC filings of Intensity Therapeutics, Inc
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Apr 19, 2024 | 8-K | Current Report | |
| Mar 14, 2024 | 8-K | Current Report | |
| Mar 14, 2024 | 10-K | Annual Report | |
| Mar 07, 2024 | 4 | Insider Trading | |
| Mar 07, 2024 | 4 | Insider Trading | |
| Mar 07, 2024 | 4 | Insider Trading | |
| Mar 07, 2024 | 4 | Insider Trading | |
| Mar 07, 2024 | 4 | Insider Trading | |
| Feb 13, 2024 | SC 13G | Major Ownership Report | |
| Feb 07, 2024 | 8-K | Current Report |
Peers (Alternatives to Intensity Therapeutics, Inc)
| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
MRNA | 47.9B | 6.8B | 23.52% | -6.94% | -8.03 | 7 | -64.45% | -224.75% |
HILS | 22.4B | 152.6K | -0.77% | 465779.94% | -2.4K | 146.8K | - | -9.98% |
ALNY | 19.3B | 2.0B | 0.99% | -25.83% | -58.02 | 9.62 | 75.20% | 68.82% |
BMRN | 15.7B | 2.5B | -4.94% | -13.58% | 76.24 | 6.34 | 13.74% | 186.89% |
INCY | 12.1B | 3.8B | -2.80% | -18.78% | 16.19 | 3.2 | 8.58% | 129.81% |
| MID-CAP | ||||||||
APLS | 5.7B | 396.6M | -16.72% | -43.78% | -10.82 | 14.42 | 425.83% | 18.94% |
BBIO | 5.2B | 107.9M | -4.79% | 106.15% | -9.53 | 48.09 | 54.84% | -28.31% |
AXSM | 3.5B | 270.6M | 1.74% | 5.10% | -14.81 | 13.09 | 440.80% | -27.84% |
ARWR | 3.0B | 240.7M | -7.74% | -39.00% | -10.2 | 12.18 | -1.03% | -92.09% |
ACAD | 2.8B | 726.4M | -7.55% | -20.97% | -45.79 | 3.86 | 40.45% | 71.62% |
| SMALL-CAP | ||||||||
CPRX | 1.7B | 398.2M | -4.91% | -11.58% | 24.31 | 4.36 | 85.90% | -14.05% |
NVAX | 687.2M | 983.7M | 8.15% | -35.14% | -1.26 | 0.7 | -50.36% | 17.16% |
CRBP | 408.0M | 881.7K | 0.99% | 345.87% | -9.15 | 466.16 | -77.61% | -5.33% |
INO | 282.8M | 4.9M | -1.94% | 21.49% | -2.09 | 58.11 | -54.97% | 51.71% |
IBIO | 6.9M | 2.1M | -32.65% | 86.79% | -0.25 | 2.14 | -13.45% | 66.37% |
Intensity Therapeutics, Inc News
Latest updates
Intensity Therapeutics, Inc Earnings Report: Key Takeaways & Analysis
Balance Sheet
(In Millions)
| Balance Sheet | (In Millions) | ||||
| Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2022Q4 |
| Assets | 2.8% | 17.00 | 17.00 | 18.00 | 2.00 |
| Current Assets | -7.0% | 15.00 | 17.00 | 18.00 | 1.00 |
| Cash Equivalents | 27.8% | 9.00 | 7.00 | 0.00 | 1.00 |
| Liabilities | 356.8% | 4.00 | 1.00 | 3.00 | 7.00 |
| Current Liabilities | 446.8% | 4.00 | 1.00 | 3.00 | 7.00 |
| Shareholder's Equity | -17.3% | 13.00 | 16.00 | 15.00 | -15.10 |
| Retained Earnings | -6.7% | -50.51 | -47.34 | -43.69 | -38.65 |
| Additional Paid-In Capital | 0.7% | 64.00 | 63.00 | 60.00 | 24.00 |
| Shares Outstanding | 0% | 14.00 | 14.00 | 13.00 | 3.00 |
Cashflow (Last 12 Months)
(In Thousands)
| Cashflow (Quarterly) | (In Thousands) | ||||||
| Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2022Q4 | 2022Q3 | 2022Q2 |
| Cashflow From Operations | 81.5% | -947 | -5,118 | - | - | - | - |
| Share Based Compensation | 20.3% | 423 | 351 | - | - | - | - |
| Cashflow From Financing | -100.1% | -12.16 | 20,521 | - | - | - | - |
INTS Income Statement
2023-12-31STATEMENTS OF OPERATIONS (Statement) - USD ($) $ in Thousands | 12 Months Ended | |
|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
| Operating expenses: | ||
| Research and development | $ 4,786 | $ 5,132 |
| General and administrative | 3,533 | 2,418 |
| Total operating expenses | 8,319 | 7,550 |
| Loss from operations | (8,319) | (7,550) |
| Other income (expense): | ||
| Interest income | 324 | 2 |
| Interest expense | (305) | (82) |
| Loss on debt extinguishment | (2,262) | 0 |
| Other | 24 | 48 |
| Net loss | (10,538) | (7,582) |
| Preferred stock deemed dividend | (1,324) | 0 |
| Net loss attributable to common stockholders | $ (11,862) | $ (7,582) |
| Loss per share, basic (in dollars per share) | $ (1.38) | $ (2.22) |
| Loss per share, diluted (in dollars per share) | $ (1.38) | $ (2.22) |
| Weighted average number of shares of common stock, basic (in shares) | 8,616,324 | 3,410,103 |
| Weighted average number of shares of common stock, diluted (in shares) | 8,616,324 | 3,410,103 |
INTS Balance Sheet
2023-12-31BALANCE SHEETS - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 8,556,000 | $ 1,312,000 |
| Marketable debt securities | 6,220,000 | 0 |
| Prepaid expenses | 682,000 | 63,000 |
| Other current assets | 6,000 | 76,000 |
| Total current assets | 15,464,000 | 1,451,000 |
| Right-of-use asset, net | 147,000 | 139,000 |
| Other assets | 1,684,000 | 167,000 |
| Total assets | 17,295,000 | 1,757,000 |
| Current liabilities: | ||
| Accounts payable | 3,048,000 | 603,000 |
| Accrued expenses | 891,000 | 1,724,000 |
| Lease liability, current portion | 20,000 | 143,000 |
| Convertible note and accrued interest | 0 | 4,349,000 |
| Total current liabilities | 3,959,000 | 6,819,000 |
| Other long-term liabilities | 36,000 | 36,000 |
| Lease liability, net of current portion | 138,000 | 0 |
| Total liabilities | 4,133,000 | 6,855,000 |
| Series A redeemable convertible preferred stock, par value $.0001. Authorized, issued, and outstanding shares of none and 5,000,000 as of December 31, 2023 and 2022, respectively. | 0 | 10,000,000 |
| Commitments and contingencies | ||
| STOCKHOLDERS’ EQUITY (DEFICIENCY) | ||
| Preferred stock, issued | 0 | 0 |
| Common stock, issued | 1,000 | 0 |
| Additional paid-in capital | 63,676,000 | 23,555,000 |
| Accumulated deficit | (50,515,000) | (38,653,000) |
| Total stockholders’ equity (deficiency) | 13,162,000 | (15,098,000) |
| Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficiency) | 17,295,000 | 1,757,000 |
| Series B Convertible Preferred | ||
| STOCKHOLDERS’ EQUITY (DEFICIENCY) | ||
| Preferred stock, issued | 0 | 0 |
| Series C Convertible Preferred | ||
| STOCKHOLDERS’ EQUITY (DEFICIENCY) | ||
| Preferred stock, issued | $ 0 | $ 0 |
| Â CEO | Mr. Lewis H. Bender M.A., M.B.A., M.S. |
|---|---|
| Â WEBSITE | https://intensitytherapeutics.com |
| Â INDUSTRY | Biotechnology |